MYC and neoplasm: This is highlighted in our analysis of event-free survival (EFS) for patients with TNBC in the pembrolizumab arm of the ISPY-2 TRIAL37, which revealed that patients with a high MYC signature in their pre-treatment tumors experienced tumor relapse or metastasis sooner than patients with a low MYC signature.